The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...
Hims & Hers Health ( NYSE: HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A ...
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable ...
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...
Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.
The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...
Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results